Association Between Obesity and Poor Prognosis in Patients Receiving Anlotinib for Advanced Non-Small Cell Lung Cancer

Background: Anlotinib is a novel anti-angiogenesis drug. In non-small cell lung cancer (NSCLC), high body mass index (BMI) was not associated with worse survival in patients treated with bevacizumab compared with those with normal or low BMI. However, it remains unknown whether such an association s...

Descripción completa

Detalles Bibliográficos
Autores principales: Xiong, Anning, Nie, Wei, Cheng, Lei, Zhong, Hua, Chu, Tianqing, Zhong, Runbo, Lu, Jun, Wang, Shuyuan, Xu, Jianlin, Shen, Yinchen, Pan, Feng, Han, Baohui, Zhang, Xueyan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9005904/
https://www.ncbi.nlm.nih.gov/pubmed/35431919
http://dx.doi.org/10.3389/fphar.2022.812555

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9005904/
https://www.ncbi.nlm.nih.gov/pubmed/35431919
http://dx.doi.org/10.3389/fphar.2022.812555

Ejemplares similares